A Phase 3 interventional study of Atezolizumab and Tiragolumab in Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche. Completed at 132 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
How we know · 9 judgments · one reading being read again
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing tiragolumab in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 2 under way, none of them phase 3. Tiragolumab · Carcinoma, Non-Small-Cell Lung.
Among the 12 studies testing tiragolumab in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by enrollment, is one of 3 that started in 2020, is one of 3 in phase 3, and was the 4th registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →1 of the 12 studies testing tiragolumab in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:
Centre Georges Francois Leclerc · Sites in France
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tiragolumab is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 4
First in 2017; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 620 is above the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 74 across the 12 interventional studies. Of the 9 that completed or were terminated, 9 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 12 have an industry lead sponsor. The 7 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 88 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche: 5 open now, 15 under way, 8 of them phase 3. Of 162 finished, 96 (59%) have results posted.
Among the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, this one is the 19th largest by enrollment of the 142 interventional ones that give a count, is one of 10 that started in 2020, is one of 48 in phase 3, and was the 152nd registered.
Hoffmann-La Roche’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2001.
1 of the studies testing tiragolumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05825625Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing tiragolumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Hoffmann-La Roche’s 182 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. Eligible participants will be randomized in a 1:1 ratio to receive either tiragolumab plus atezolizumab or placebo plus atezolizumab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
Drug: Atezolizumab · Drug: Tiragolumab
Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
Drug: Atezolizumab · Drug: Matching Placebo
Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
Also known as: Tecentriq
Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Also known as: MTIG7192A
Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Global Cohort: Investigator-assessed Progression-free Survival (PFS) After Randomization According to RECIST v1.1 in the Primary Analysis Set (PAS)
PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm) or unequivocal progression of existing non-target lesions. Kaplan-Meier (K-M) method was used to estimate the median PFS.
Time frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
China Cohort: Investigator-assessed PFS After Randomization According to RECIST v1.1 in the PAS
PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.
Time frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
Global Cohort: Overall Survival (OS) in the PAS
OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS.
Time frame: From randomization to death from any cause (up to approximately 54.7 months)
China Cohort: OS in the PAS
OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS.
Time frame: From randomization to death from any cause (up to approximately 49.1 months)
Global Cohort: Number of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Up to 65.1 months
China Cohort: Number of Participants With AEs
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Up to 49.3 months
Global Cohort: Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined by American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale
CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, \& end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension \& hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS.
Time frame: Up to 65.1 months
China Cohort: Number of Participants With CRS, With Severity Determined by ASTCT Consensus Grading Scale
CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, \& end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension \& hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS.
Time frame: Up to 49.3 months
Global Cohort: Investigator-assessed PFS According to RECIST v1.1 in the Secondary Analysis Set (SAS)
PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.
Time frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
China Cohort: Investigator-assessed PFS According to RECIST v1.1 in the SAS
PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.
Time frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
Global Cohort: OS in the SAS
OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS.
Time frame: From randomization to death from any cause (up to approximately 54.7 months)
China Cohort: OS in the SAS
OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS.
Time frame: From randomization to death from any cause (up to approximately 49.1 months)
Global Cohort: Investigator-assessed Confirmed Objective Response Rate (ORR) According to RECIST v1.1 in the PAS
Confirmed ORR was defined as the percentage of participants with a confirmed objective response (OR), characterized by either a complete response (CR) or a partial response (PR), on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions \& normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.
Time frame: Up to approximately 54.6 months
China Cohort: Investigator-assessed Confirmed ORR According to RECIST v1.1 in the PAS
Confirmed ORR was defined as the percentage of participants with a confirmed OR, characterized by either a CR or a PR, on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions \& normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.
Time frame: Up to 49.3 months
Global Cohort: Investigator-assessed Duration of Response (DOR) According to RECIST v1.1 for Participants With Confirmed ORR in the PAS
DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target \& non-target lesions \& normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR.
Time frame: From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 54.6 months)
China Cohort: Investigator-assessed DOR According to RECIST v1.1 for Participants With Confirmed ORR in the PAS
DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target \& non-target lesions \& normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR.
Time frame: From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to 49.3 months)
Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS
PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.
Time frame: At Months 6 and 12
China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS
PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.
Time frame: At Months 6 and 12
Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS
PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.
Time frame: At Months 6 and 12
China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS
PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.
Time frame: At Months 6 and 12
Global Cohort: OS Rate at 12 Months and 24 Months in the PAS
OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.
Time frame: At Months 12 and 24
China Cohort: OS Rate at 12 Months and 24 Months in the PAS
OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.
Time frame: At Months 12 and 24
Global Cohort: OS Rate at 12 Months and 24 Months in the SAS
OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.
Time frame: At Months 12 and 24
China Cohort: OS Rate at 12 Months and 24 Months in the SAS
OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.
Time frame: At Months 12 and 24
Global Cohort: Time to Confirmed Deterioration (TTCD) in Participant-reported Physical Functioning (PF), as Measured by European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) in the PAS
TTCD was defined as the time from randomization to first confirmed clinically meaningful deterioration (CCMD). EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), global health status (GHS)/quality-of-life (QoL), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.
Time frame: Up to approximately 54.6 months
China Cohort: TTCD in Participant-reported PF, as Measured by EORTC QLQ-C30 in the PAS
TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.
Time frame: Up to approximately 49.3 months
Global Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS
TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better health-related quality-of-life (HRQoL). CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.
Time frame: Up to approximately 54.6 months
China Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS
TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better HRQoL. CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.
Time frame: Up to approximately 49.3 months
Global Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
Time frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-end of infusion (EOI) on Day 1 of Cycle 1; Treatment discontinuation (TD) visit (up to approximately 54.6 months) (1 Cycle=21 days)
China Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
Time frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Global Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
Time frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 54.6 months) (1 Cycle=21 days)
China Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
Time frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Global Cohort: Number of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.
Time frame: Up to approximately 54.6 months
China Cohort: Number of Participants With ADAs to Tiragolumab
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.
Time frame: Up to approximately 49.3 months
Global Cohort: Number of Participants With ADAs to Atezolizumab
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.
Time frame: Up to approximately 54.6 months
China Cohort: Number of Participants With ADAs to Atezolizumab
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.
Time frame: Up to approximately 49.3 months
A total of 620 participants with previously untreated locally advanced, unresectable or metastatic programmed death-ligand 1 (PD-L1)-selected non-small cell lung cancer (NSCLC) with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation took part in the Global \& China extension cohorts of the study at 141 investigative sites across 23 countries from 03 March 2020 to 30 December 2025.
| Milestone | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab | China Cohort Only: Placebo + Atezolizumab | China Cohort Only: Tiragolumab + Atezolizumab |
|---|---|---|---|---|
| Started | 268 | 266 | 41 | 45 |
| Global cohort | 268 | 266 | 0 | 0 |
| China cohort | 0 | 0 | 48 | 52 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 268 | 266 | 41 | 45 |
| Withdrew: Symptomatic deterioration | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Death | 171 | 170 | 19 | 21 |
| Withdrew: Study ended by sponsor | 74 | 73 | 19 | 21 |
| Withdrew: Withdrawal by subject | 20 | 21 | 2 | 2 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 | 1 |
| Withdrew: Reason not specified | 0 | 0 | 1 | 0 |
PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.
| months | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Global Cohort: Investigator-assessed PFS According to RECIST v1.1 in the Secondary Analysis Set (SAS) | 5.91 (4.99 to 7.26) | 8.25 (6.44 to 12.22) |
PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.
| months | China Cohort: Placebo + Atezolizumab | China Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| China Cohort: Investigator-assessed PFS According to RECIST v1.1 in the SAS | 8.25 (6.24 to 15.24) | 7.82 (5.09 to 15.70) |
OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS.
| months | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Global Cohort: OS in the SAS | 20.57 (16.59 to 29.34) | 24.64 (17.87 to 31.97) |
OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS.
| months | China Cohort: Placebo + Atezolizumab | China Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| China Cohort: OS in the SAS | NA (29.27 to NA) | NA (21.91 to NA) |
Confirmed ORR was defined as the percentage of participants with a confirmed objective response (OR), characterized by either a complete response (CR) or a partial response (PR), on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions \& normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.
| percentage of participants | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Global Cohort: Investigator-assessed Confirmed Objective Response Rate (ORR) According to RECIST v1.1 in the PAS | 35.1 (29.39 to 41.33) | 45.8 (39.69 to 52.04) |
Confirmed ORR was defined as the percentage of participants with a confirmed OR, characterized by either a CR or a PR, on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions \& normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.
| percentage of participants | China Cohort: Placebo + Atezolizumab | China Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| China Cohort: Investigator-assessed Confirmed ORR According to RECIST v1.1 in the PAS | 47.9 (33.52 to 62.64) | 48.1 (34.22 to 62.22) |
DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target \& non-target lesions \& normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR.
| months | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Global Cohort: Investigator-assessed Duration of Response (DOR) According to RECIST v1.1 for Participants With Confirmed ORR in the PAS | 14.6 (9.7 to 18.6) | 18.0 (13.6 to 24.4) |
DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target \& non-target lesions \& normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR.
| months | China Cohort: Placebo + Atezolizumab | China Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| China Cohort: Investigator-assessed DOR According to RECIST v1.1 for Participants With Confirmed ORR in the PAS | 13.9 (9.4 to NA) | 18.0 (11.8 to 25.8) |
PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.
| percentage of participants | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Month 6 | 47.84 (41.67 to 54.01) | 54.62 (48.50 to 60.74) |
| Month 12 | 24.86 (18.78 to 30.94) | 37.27 (30.62 to 43.92) |
PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.
| percentage of participants | China Cohort: Placebo + Atezolizumab | China Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Month 6 | 63.17 (49.24 to 77.10) | 58.82 (45.32 to 72.33) |
| Month 12 | 37.03 (23.07 to 50.99) | 42.26 (28.50 to 56.01) |
PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.
| percentage of participants | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Month 6 | 49.54 (42.66 to 56.42) | 57.42 (50.66 to 64.18) |
| Month 12 | 27.06 (19.95 to 34.17) | 42.60 (35.15 to 50.06) |
PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.
| percentage of participants | China Cohort: Placebo + Atezolizumab | China Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Month 6 | 66.83 (52.61 to 81.05) | 58.33 (44.39 to 72.28) |
| Month 12 | 40.58 (25.72 to 55.43) | 42.83 (28.62 to 57.05) |
OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.
| percentage of participants | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Month 12 | 62.62 (56.66 to 68.58) | 67.28 (61.53 to 73.03) |
| Month 24 | 41.93 (35.80 to 48.05) | 47.66 (41.49 to 53.82) |
OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.
| percentage of participants | China Cohort: Placebo + Atezolizumab | China Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Month 12 | 87.02 (77.32 to 96.72) | 77.84 (66.26 to 89.42) |
| Month 24 | 62.49 (47.68 to 77.29) | 59.40 (44.79 to 74.01) |
OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.
| percentage of participants | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Month 12 | 67.60 (61.21 to 73.98) | 68.19 (61.85 to 74.54) |
| Month 24 | 46.27 (39.42 to 53.12) | 50.29 (43.42 to 57.15) |
OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.
| percentage of participants | China Cohort: Placebo + Atezolizumab | China Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Month 12 | 92.97 (85.29 to 100.00) | 78.55 (66.73 to 90.36) |
| Month 24 | 68.56 (53.57 to 83.55) | 61.01 (45.90 to 76.12) |
TTCD was defined as the time from randomization to first confirmed clinically meaningful deterioration (CCMD). EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), global health status (GHS)/quality-of-life (QoL), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.
| months | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Global Cohort: Time to Confirmed Deterioration (TTCD) in Participant-reported Physical Functioning (PF), as Measured by European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) in the PAS | 16.46 (11.10 to 33.28) | 16.53 (13.83 to 28.91) |
TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.
| months | China Cohort: Placebo + Atezolizumab | China Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| China Cohort: TTCD in Participant-reported PF, as Measured by EORTC QLQ-C30 in the PAS | NA (14.95 to NA) | NA (18.43 to NA) |
TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better health-related quality-of-life (HRQoL). CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.
| months | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Global Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS | 15.54 (11.70 to 32.26) | 22.77 (15.28 to 37.72) |
TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better HRQoL. CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.
| months | China Cohort: Placebo + Atezolizumab | China Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| China Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS | NA (13.54 to NA) | NA (NA to NA) |
| micrograms per milliliter (µg/mL) | Global Cohort: Tiragolumab + Atezolizumab |
|---|---|
| Pre-dose on Day 1 of Cycle 1 | NA ± NA |
| 30 Minutes EOI on Day 1 of Cycle 1 | 217 ± 35.2 |
| Pre-dose on Day 1 of Cycle 2 | 22.3 ± 242.4 |
| Pre-dose on Day 1 of Cycle 3 | 43.2 ± 69.2 |
| Pre-dose on Day 1 of Cycle 4 | 57.3 ± 62.2 |
| Pre-dose on Day 1 of Cycle 8 | 66.7 ± 81.5 |
| Pre-dose on Day 1 of Cycle 12 | 72.4 ± 138.8 |
| Pre-dose on Day 1 of Cycle 16 | 71.3 ± 139.4 |
| TD Visit | 21.5 ± 541.6 |
| µg/mL | China Cohort: Tiragolumab + Atezolizumab |
|---|---|
| Pre-dose on Day 1 of Cycle 1 | NA ± NA |
| 30 Minutes Post-EOI on Day 1 of Cycle 1 | 199 ± 26.4 |
| Pre-dose on Day 1 of Cycle 2 | 26.4 ± 49.8 |
| Pre-dose on Day 1 of Cycle 3 | 40.3 ± 71.1 |
| Pre-dose on Day 1 of Cycle 4 | 40.7 ± 305.5 |
| Pre-dose on Day 1 of Cycle 8 | 64.9 ± 42.6 |
| Pre-dose on Day 1 of Cycle 12 | 63.4 ± 28.0 |
| Pre-dose on Day 1 of Cycle 16 | 59.1 ± 77.4 |
| TD Visit | 38.5 ± 130.0 |
| µg/mL | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Pre-dose on Day 1 of Cycle 1 | NA ± NA | NA ± NA |
| 30 Minutes Post-EOI on Day 1 of Cycle 1 | 414 ± 29.1 | 427 ± 27.7 |
| Pre-dose on Day 1 of Cycle 2 | 68.3 ± 54.7 | 64.2 ± 130.6 |
| Pre-dose on Day 1 of Cycle 3 | 99.9 ± 125.3 | 112 ± 58.1 |
| Pre-dose on Day 1 of Cycle 4 | 123 ± 115.7 | 139 ± 64.4 |
| Pre-dose on Day 1 of Cycle 8 | 170 ± 106.8 | 180 ± 47.8 |
| Pre-dose on Day 1 of Cycle 12 | 209 ± 45.0 | 190 ± 89.0 |
| Pre-dose on Day 1 of Cycle 16 | 215 ± 42.2 | 206 ± 47.1 |
| TD Visit | 91.9 ± 221.2 | 61.5 ± 346.5 |
| µg/mL | China Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Pre-dose on Day 1 of Cycle 1 | NA ± NA | NA ± NA |
| 30 Minutes Post-EOI on Day 1 of Cycle 1 | 467 ± 16.5 | 466 ± 18.5 |
| Pre-dose on Day 1 of Cycle 2 | 68.8 ± 69.1 | 74.9 ± 35.5 |
| Pre-dose on Day 1 of Cycle 3 | 105 ± 71.2 | 115 ± 55.0 |
| Pre-dose on Day 1 of Cycle 4 | 127 ± 55.8 | 144 ± 34.0 |
| Pre-dose on Day 1 of Cycle 8 | 157 ± 48.0 | 175 ± 32.9 |
| Pre-dose on Day 1 of Cycle 12 | 169 ± 69.9 | 176 ± 28.9 |
| Pre-dose on Day 1 of Cycle 16 | 190 ± 34.4 | 187 ± 57.5 |
| TD Visit | 100 ± 87.4 | 123 ± 72.8 |
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.
| Participants | Global Cohort: Tiragolumab + Atezolizumab |
|---|---|
| Global Cohort: Number of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab | 5 |
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.
| Participants | China Cohort: Tiragolumab + Atezolizumab |
|---|---|
| China Cohort: Number of Participants With ADAs to Tiragolumab | 1 |
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.
| Participants | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Global Cohort: Number of Participants With ADAs to Atezolizumab | 62 | 63 |
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.
| Participants | China Cohort: Placebo + Atezolizumab | China Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| China Cohort: Number of Participants With ADAs to Atezolizumab | 16 | 25 |
PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm) or unequivocal progression of existing non-target lesions. Kaplan-Meier (K-M) method was used to estimate the median PFS.
| months | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Global Cohort: Investigator-assessed Progression-free Survival (PFS) After Randomization According to RECIST v1.1 in the Primary Analysis Set (PAS) | 5.55 (4.37 to 7.03) | 7.00 (5.62 to 9.79) |
PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.
| months | China Cohort: Placebo + Atezolizumab | China Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| China Cohort: Investigator-assessed PFS After Randomization According to RECIST v1.1 in the PAS | 7.16 (5.68 to 13.17) | 7.82 (5.09 to 15.15) |
OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS.
| months | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Global Cohort: Overall Survival (OS) in the PAS | 16.85 (14.59 to 21.32) | 23.13 (17.71 to 28.78) |
OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS.
| months | China Cohort: Placebo + Atezolizumab | China Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| China Cohort: OS in the PAS | 29.67 (21.88 to NA) | 28.29 (15.70 to NA) |
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| Participants | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Global Cohort: Number of Participants With Adverse Events (AEs) | 241 | 256 |
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| Participants | China Cohort: Placebo + Atezolizumab | China Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| China Cohort: Number of Participants With AEs | 48 | 51 |
CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, \& end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension \& hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS.
| Participants | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| Global Cohort: Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined by American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale | 0 | 2 |
CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, \& end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension \& hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS.
| Participants | China Cohort: Placebo + Atezolizumab | China Cohort: Tiragolumab + Atezolizumab |
|---|---|---|
| China Cohort: Number of Participants With CRS, With Severity Determined by ASTCT Consensus Grading Scale | 0 | 0 |
Collected over Global cohort: Up to 65.1 months; China Cohort: 49.3 months. As pre-specified in SAP, participants enrolled from China during the global enrollment phase were included in the analysis for the China cohort, hence, 15 participants from Global cohorts were included in China cohorts for all analysis.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Global Cohort: Placebo + Atezolizumab | 179/263 (68.1%) | 108/263 (41.1%) | 217/263 (82.5%) |
| Global Cohort: Tiragolumab + Atezolizumab | 175/267 (65.5%) | 117/267 (43.8%) | 239/267 (89.5%) |
| China Cohort: Placebo + Atezolizumab | 21/48 (43.8%) | 12/48 (25%) | 47/48 (97.9%) |
| China Cohort: Tiragolumab + Atezolizumab | 24/52 (46.2%) | 20/52 (38.5%) | 48/52 (92.3%) |
| Event | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab | China Cohort: Placebo + Atezolizumab | China Cohort: Tiragolumab + Atezolizumab |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 14/263 | 13/267 | 3/48 | 7/52 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 0/263 | 0/267 | 0/48 | 3/52 |
| COVID-19Infections and infestations | 12/263 | 6/267 | 0/48 | 0/52 |
| Immune-mediated lung diseaseRespiratory, thoracic and mediastinal disorders | 0/263 | 0/267 | 1/48 | 2/52 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 7/263 | 3/267 | 0/48 | 0/52 |
| DeathGeneral disorders | 2/263 | 7/267 | 0/48 | 0/52 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 6/263 | 6/267 | 1/48 | 0/52 |
| Retinal artery occlusionEye disorders | 1/263 | 0/267 | 1/48 | 0/52 |
| PainGeneral disorders | 1/263 | 0/267 | 1/48 | 0/52 |
| PyrexiaGeneral disorders | 5/263 | 3/267 | 1/48 | 1/52 |
| Event | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab | China Cohort: Placebo + Atezolizumab | China Cohort: Tiragolumab + Atezolizumab |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 41/263 | 41/267 | 15/48 | 23/52 |
| Aspartate aminotransferase increasedInvestigations | 28/263 | 29/267 | 8/48 | 16/52 |
| PruritusSkin and subcutaneous tissue disorders | 47/263 | 79/267 | 8/48 | 16/52 |
| Alanine aminotransferase increasedInvestigations | 28/263 | 37/267 | 7/48 | 15/52 |
| RashSkin and subcutaneous tissue disorders | 35/263 | 67/267 | 8/48 | 14/52 |
| HyperglycaemiaMetabolism and nutrition disorders | 11/263 | 17/267 | 12/48 | 7/52 |
| COVID-19Infections and infestations | 27/263 | 33/267 | 7/48 | 12/52 |
| CoughRespiratory, thoracic and mediastinal disorders | 28/263 | 41/267 | 11/48 | 5/52 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 7/263 | 7/267 | 9/48 | 10/52 |
| Decreased appetiteMetabolism and nutrition disorders | 32/263 | 51/267 | 9/48 | 6/52 |
Full analysis set (FAS) included all randomized participants, regardless of whether participants received the assigned treatment.
| Age, Customized(Participants) | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab | China Cohort Only: Placebo + Atezolizumab | China Cohort Only : Tiragolumab + Atezolizumab | Total |
|---|---|---|---|---|---|
| < 65 years | 120 | 111 | 18 | 18 | 267 |
| ≥ 65 years | 148 | 155 | 23 | 27 | 353 |
| Sex: Female, Male(Participants) | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab | China Cohort Only: Placebo + Atezolizumab | China Cohort Only : Tiragolumab + Atezolizumab | Total |
|---|---|---|---|---|---|
| Female | 72 | 64 | 7 | 7 | 150 |
| Male | 196 | 202 | 34 | 38 | 470 |
| Ethnicity (NIH/OMB)(Participants) | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab | China Cohort Only: Placebo + Atezolizumab | China Cohort Only : Tiragolumab + Atezolizumab | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 21 | 11 | 0 | 0 | 32 |
| Not Hispanic or Latino | 244 | 254 | 40 | 43 | 581 |
| Unknown or Not Reported | 3 | 1 | 1 | 2 | 7 |
| Race (NIH/OMB)(Participants) | Global Cohort: Placebo + Atezolizumab | Global Cohort: Tiragolumab + Atezolizumab | China Cohort Only: Placebo + Atezolizumab | China Cohort Only : Tiragolumab + Atezolizumab | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 5 | 3 | 0 | 0 | 8 |
| Asian | 73 | 72 | 41 | 45 | 231 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 0 | 0 | 4 |
| White | 184 | 185 | 0 | 0 | 369 |
| More than one race | 1 | 2 | 0 | 0 | 3 |
| Unknown or Not Reported | 3 | 2 | 0 | 0 | 5 |
Showing the first 100 of 132 sites across 23 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Mar 2020 to primary completion in Dec 2025, 69 months.
Results were first posted in Nov 2026, 10 months after primary completion.
Of 314 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 69 months is above that.
Counting every sponsor, half of 423 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tiragolumab
Carcinoma, Non-Small-Cell Lung →